External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

Inclusion Criteria:

* Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC
* Must have received at least one line of systemic therapy for locally advanced (non-resectable) or metastatic RET-fusion positive NSCLC, which may include regimens containing:

  * Chemotherapy, e.g., regimens containing platinum doublet-based therapy (carboplatin, cisplatin)
  * Chemotherapy in combination with other drugs will be assessed, e.g., in combination with pemetrexed, immune checkpoint inhibitors (pembrolizumab), bevacizumab
  * Ramucirumab in combination with docetaxel
  * Immune checkpoint inhibitors, e.g., pembrolizumab, nivolumab, and atezolizumab
  * MKIs, e.g., cabozantinib, alectinib, vandetanib, sunitinib, and nintedanib
* Must be aged ≥18 years of age at the initiation of first systemic line of therapy
* Must have availabile of performance status (e.g., Eastern Cooperative Oncology Group \[ECOG\] score or Karnofsky score)
* Must have an index date at least 3 months prior to the start of data collection (in order to include patients with at least 3 months of follow-up after index date), unless date of death occurred less than three months from index date
* Must have an approved waiver of informed consent or signed informed consent for participation in the retrospective chart review study, as applicable

Exclusion Criteria:

* Known primary driver alteration other than RET (e.g., targetable mutation in EGFR, ALK, ROS1, or BRAF)
* History of other malignancy, other than non-melanoma skin cancer, within 1 year prior to initiation of first systemic therapy
* Received pralsetinib as the first line of systemic therapy for RET-fusion positive NSCLC, or prior to initiation of first systemic therapy